Business
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today prov
About this update from Polypid Ltd.
[{"type":"image","alt":"PolyPid Ltd.","displaySize":"","headline":null,"caption":"PolyPid Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":277,"url":"https://media.zenfs.com/en/globenewswire.com/4d560867e2683410f51b476a7e0357fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/myrb4tbW43JSa6V.OvnEZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4d560867e2683410f51b476a7e0357fe","width":300,"height":277}},"lazy":false},{"type":"text","content":"PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100, with Top-Line Results Anticipated in Current Quarter","length":135,"tagName":"p"},{"type":"text","content":"Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions","length":122,"tagName":"p"},{"type":"text","content":"Conference Call Scheduled for Today at 8:30 AM ET","length":49,"tagName":"p"},{"type":"text","content":"PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2025.","length":298,"tagName":"p"},{"type":"text","content":"Recent Corporate Highlights:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Clinical Development: Successfully completed enrollment of 800 patients in the SHIELD II Phase 3 trial of D-PLEX100 for the prevention of abdominal colorectal surgical site infections. This major achievement follows the independent Data Safety Monitoring Board’s (“DSMB”) recommendation to conclude the study at the lowest sample size reassessment option, potentially suggestive of positive efficacy signals from D-PLEX100.","length":423,"tagName":"p"}]},{"val":[{"type":"text","content":"Near-term Catalyst Timeline: Top-line results from SHIELD II remain on track and expected to be announced by the end of the current quarter (the second quarter of 2025), representing a potentially transformative milestone for the Company.","length":238,"tagName":"p"}]},{"val":[{"type":"text","content":"Regulatory Pathway: Following potential positive Phase 3 data, PolyPid plans to leverage its Fast Track and Breakthroug...